IP Library › Granted Patent US 12,410,479
Granted Patent B2
US 12,410,479 · App. 17/554,476 · Granted Sep 9, 2025

Microrna assay for detection and management of pancreatic cancer precursors

Inventors: Mokenge P. Malafa (Tampa, FL); Jennifer Permuth (Tampa, FL); Dung-Tsa Chen (Tampa, FL)
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
C12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,479
App. No.
17/554,476
Granted
Sep 9, 2025
Kind
B2
Abstract

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

Claims (7)

1. A method of treating and/or delaying onset of the development of pancreatic cancer in a subject, the method comprising:

(a) detecting the level of expression of let-7a-5p, let-7d-5p, let-7f-5p, let-7g-5p, let-7i-5p, miR-107, miR-1260b, miR-126-3p, miR-142-3p, miR-145-5p, miR-146a-5p, miR-148a-3p, miR-15b-5p, miR-181a-5p, miR-191-5p, miR-199b-3p, miR-20a-5p, miR-20b-5p, miR-22-3p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-27a-3p, miR-29c-3p, miR-335-5p, miR-337-5p, miR-340-5p, miR-423-5p, miR-4454, miR-593-3p, miR-98, miR-200a-3p, miR-1185-5p, miR-33a-5p, miR-574-3p, miR-663b, miR-99b, miR-342-3p, miR-126, miR-888, miR-130a, let-7c, miR-296, and miR-302a in a body fluid sample or pancreatic tissue sample from the subject;

(b) comparing the detected expression level to a reference expression level, wherein a differential expression of let-7a-5p, let-7d-5p, let-7f-5p, let-7g-5p, let-7i-5p, miR-107, miR-1260b, miR-126-3p, miR-142-3p, miR-145-5p, miR-146a-5p, miR-148a-3p, miR-15b-5p, miR-181a-5p, miR-191-5p, miR-199b-3p, miR-20a-5p, miR-20b-5p, miR-22-3p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-27a-3p, miR-29c-3p, miR-335-5p, miR-337-5p, miR-340-5p, miR-423-5p, miR-4454, miR-593-3p, miR-98, miR-200a-3p, miR-1185-5p, miR-33a-5p, miR-574-3p, miR-663b, miR-99b, miR-342-3p, miR-126, miR-888, miR-130a, let-7c, miR-296, and miR-302a in the body fluid sample or pancreatic tissue sample, as compared to the reference expression level, is indicative of the presence of pancreatic cancer, or a higher risk of developing pancreatic cancer, versus the absence of pancreatic cancer, or a lower risk of developing pancreatic cancer, respectively; and

(c) administering a therapy to treat and/or delay onset of the pancreatic cancer to the subject identified as having the pancreatic cancer, or at a higher risk of developing pancreatic cancer; wherein the therapy comprises surgical resection, pancreatoduodenectomy (Whipple procedure), chemotherapy, radiation, immunotherapy, or a combination of two or more of the foregoing.

2. The method of claim 1 , wherein a differential expression of let-7a-5p, let-7d-5p, let-7f-5p, let-7g-5p, let-7i-5p, miR-107, miR-1260b, miR-126-3p, miR-142-3p, miR-145-5p, miR-146a-5p, miR-148a-3p, miR-15b-5p, miR-181a-5p, miR-191-5p, miR-199b-3p, miR-20a-5p, miR-20b-5p, miR-22-3p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-27a-3p, miR-29c-3p, miR-335-5p, miR-337-5p, miR-340-5p, miR-423-5p, miR-4454, miR-593-3p, miR-98, miR-200a-3p, miR-1185-5p, miR-33a-5p, miR-574-3p, miR-663b, miR-99b, miR-342-3p, miR-126, miR-888, miR-130a, let-7c, miR-296, and miR-302a in the body fluid sample or pancreatic tissue sample, as compared to the reference expression level, is indicative of a pancreatic cancer precursor (such as intraductal papillary mucinous neoplasm (IPMN)) versus non-IPMN (normal cells).

3. A method of treating and/or preventing delaying onset of pancreatic cancer in a subject, comprising measuring the level of expression of let-7a-5p, let-7d-5p, let-7f-5p, let-7g-5p, let-7i-5p, miR-107, miR-1260b, miR-126-3p, miR-142-3p, miR-145-5p, miR-146a-5p, miR-148a-3p, miR-15b-5p, miR-181a-5p, miR-191-5p, miR-199b-3p, miR-20a-5p, miR-20b-5p, miR-22-3p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-27a-3p, miR-29c-3p, miR-335-5p, miR-337-5p, miR-340-5p, miR-423-5p, miR-4454, miR-593-3p, miR-98, miR-200a-3p, miR-1185-5p, miR-33a-5p, miR-574-3p, miR-663b, miR-99b, miR-342-3p, miR-126, miR-888, miR-130a, let-7c, miR-296, and miR-302a in a body fluid sample or pancreatic tissue sample obtained from the subject; and administering a treatment for the pancreatic cancer;

wherein the treatment comprises surgical resection, pancreatoduodenectomy (Whipple procedure), chemotherapy, radiation, immunotherapy, or a combination of two or more of the foregoing.

Continuity (5)
Continuation 17233855 · Apr 19, 2021
Continuation 16362623 · Mar 23, 2019
Continuation 15300808
Provisional Application 61973068 · Mar 31, 2014
Related Publication 20220356528A1 · Nov 10, 2022
References Cited (63)
US 7919237B2 · Dimitrov et al. · 2011 [cited by applicant]
US 8415102B2 · Geiss et al. · 2013 [cited by applicant]
US 8519115B2 · Webster et al. · 2013 [cited by applicant]
US 10240208B2 · Malafa · 2019 [cited by examiner]
US 20130324589A1 · Croce et al. · 2013 [cited by applicant]
Harvey V. Fineberg (JAMA, 2013 vol. 310:85-90). [cited by examiner]
The American Cancer Society. Can Pancreatic Cancer Be Prevented, Last Revised: Jun. 9, 2020. [cited by examiner]
Gagner and Palermo (J. Hepatobiliary Pancreatic Surgery, 2009 vol. 16:726-730). [cited by examiner]
Dahlman et al. (Am J Physiol Endocrinol Metab 312: E482-E494, 2017). [cited by examiner]
Metcalf et al. (Oncogene, Jun. 5, 2024, doi: 10.1038/s41388-024-030763, pp. 1-8). [cited by examiner]
Abdalla, M. et al., “Effect of RNA Isolation Method on microRNA Quantity and Quality in Plasma: a Comparative Study,” Norgen Biotek Corporation Application Note 49: RNA Sample Preparation, 2011, pp. 1-4. [cited by applicant]
Bergmann, U. et al., “Increased expression of insulin receptor substrate-1 in human pancreatic cancer,” [cited by applicant]
Blondal, T. et al., “Assessing sample and miRNA profile quality in serum and plasma or other biofluids,” [cited by applicant]
Canto, M.I. et al., “International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer,” [cited by applicant]
Chen, D.T. et al., “Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer,” [cited by applicant]
Chen, D.T. et al., “Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue,” [cited by applicant]
Chiyomaru, T. et al., “Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer,” [cited by applicant]
Farina, N.H. et al., “Standardizing analysis of circulating microRNA: clinical and biological relevance,” [cited by applicant]
Fourie, N.H. et al., “Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome,” [cited by applicant]
Frampton, A.E. et al., “Loss of miR-126 is crucial to pancreatic cancer progression,” [cited by applicant]
Ganepola, G.A. et al., “Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer,” [cited by applicant]
Gao, L. et al., “miR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4,” [cited by applicant]
Geiss, G.K. et al., “Direct multiplexed measurement of gene expression with color-coded probe pairs,” [cited by applicant]
Greenbaum, D. et al., “Comparing protein abundance and mRNA expression levels on a genomic scale,” [cited by applicant]
Henry, J.C. et al., “MicroRNA from Pancreatic Duct Aspirate Differentiates Cystic Lesions of the Pancreas,” [cited by applicant]
Hirata, H. et al., “Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells,” [cited by applicant]
Hruban, R.H. et al., “Precursors to pancreatic cancer,” [cited by applicant]
Hu, J. et al., “Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients,” [cited by applicant]
Jiao, L.R. et al., “MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors,” [cited by applicant]
Kapoor, S., “miR-145 and its influence on tumor growth in systemic malignancies,” [cited by applicant]
Kirschner, M.B. et al., “The Impact of Hemolysis on Cell-Free microRNA Biomarkers,” [cited by applicant]
Lee, L.S. et al. “Investigating microRNA expression profiles in pancreatic cystic neoplasms,” [cited by applicant]
Li, A. et al., “Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels,” [cited by applicant]
Li, A. et al., “MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls,” [cited by applicant]
Li, B.H. et al., “Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein,” [cited by applicant]
Liu, J. et al., “MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1,” [cited by applicant]
Liu, R. et al., “Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer,” [cited by applicant]
Lubezky, N. et al., “MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas,” [cited by applicant]
Matthaei, H. et al., “miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts,” [cited by applicant]
Mitchell, P.S. et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” [cited by applicant]
Nissim, S. et al., “Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis,” [cited by applicant]
Permuth-Wey, J. et al., “A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pa… [cited by applicant]
Permuth-Wey, J. et al., “Tackling a clinical challenge: Using microRNAs to differentiate between low-and high-risk Pancreatic Cysts,” [cited by applicant]
Permuth-Wey, J. et al., “Tackling a clinical challenge: Using microRNAs to differentiate between low-and high-risk Pancreatic Cysts,” poster presented at Proceedings of the 104th Annual Meeting of the American Associati… [cited by applicant]
Pritchard, C.C. et al., “Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies,” [cited by applicant]
Sachs, T. et al., “The incidental asymptomatic pancreatic lesion: nuisance or threat?,” [cited by applicant]
Schultz, N.A. et al., “MicroRNA biomarkers in whole blood for detection of pancreatic cancer,” [cited by applicant]
Su, Y. et al., “Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p,” [cited by applicant]
Sun, D. et al., “miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation,” [cited by applicant]
Suryawanshi, S. et al., “Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer,” [cited by applicant]
Tanaka, M. et al., “International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas,” [cited by applicant]
Tang, S. et al., “Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer,” [cited by applicant]
Wang, H. et al., “MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1,” [cited by applicant]
Wang, J. et al., “MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease,” [cited by applicant]
Weichert, W. et al., “Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer,” [cited by applicant]
Wu, J. et al., “Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development,” [cited by applicant]
Yachida, S. et al., “Distant metastasis occurs late during the genetic evolution of pancreatic cancer,” [cited by applicant]
Zhang, D.X. et al., “Prognostic factors in patients with pancreatic cancer,” [cited by applicant]
Zhang, J.J. et al., “Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma,” [cited by applicant]
Gagner, M. and Palermo, M. “Laparoscopic Whipple procedure: review of the literature” [cited by applicant]
“Can Pancreatic Cancer Be Prevented?” Written by The American Cancer Society Medical and Editorial Content Team. 2016. Downloaded from www.cancer.org/cancer/pancreatic-cancer/causes-risksprevention/prevention.html on Ja… [cited by applicant]
Fineberg, H. “The paradox of disease prevention celebrated in principle, resisted in practice” [cited by applicant]
Bauer et al., “Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue” (plus Supplementary Information), vol. 7, issue 7, 2012, e34151, PLOS Journ… [cited by applicant]